PET/CT in the Management of Patients With Early Stage Endometrial Cancer

Status Not yet recruiting

Clinical Trial Summary

Endometrial cancer (EC) is the most common gynecologic malignancy in the developed countries and is the fifth most common cancer among women worldwide. Typically present well or moderately differentiated, early stage endometrioid histotype with a prognosis usually favorable. Pelvic lymph nodes (LNs) represent the most common site of extra-uterine disease in patients with clinical early stage disease and the role of lymphadenectomy in early stage EC has been one of the major controversies in gynecology oncology. Lymphadenectomy doesn't improve survival or reduce disease recurrence although supported to provide prognostic information and allowing tailoring of adjuvant therapy. Nevertheless, lymphadenectomy is not performed without serious short-term and long-term morbidity. Although surgical staging is the most accurate and standard method to determine LNs involvement, the introduction in clinical practice of a non-invasive modality that allows an accurate staging of EC would be essential. Available evidence report the accuracy of Positron Emission Tomography and Computed Tomography (PET/CT) for the detection of LN metastasis in EC with a sensitivity of 63% and specificity of 94.7%. This prospective comparative analysis between PET/CT, histological findings, and follow up data will be performed to investigate the sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and accuracy of integrated PET/CT for nodal staging of EC per patient and per LN chain analyses, in women affected by intermediate (grade 1 and 2 endometrioid lesions with deep myometrial invasion > 50% or grade 3 endometrioid lesion with < 50% myometrial invasion) or high risk (grade 3 endometrioid lesion with deep myometrial invasion > 50% or non-endometrioid histotype) early-stage EC. Furthermore, the preoperative classification of EC in intermediate and high-risk class will allow to investigate its prognostic value.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03570866
Study type	Observational
Source	Università degli Studi dell'Insubria
Contact	Antonio Simone Laganà, M.D.
Phone	?+39 329 6279579?
Email	antoniosimone.lagana@asst-settelaghi.it
Status	Not yet recruiting
Phase
Start date	May 1, 2022
Completion date	May 1, 2024

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05036681` - A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial Carcinoma	Phase 2
Completed	`NCT00377520` - A Trial for Patients With Advanced/Recurrent Endometrial Cancer	Phase 2
Recruiting	`NCT06192017` - Development of a Molecular Diagnostic Tool for Endometrial Cancer.
Recruiting	`NCT05902988` - A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer	Phase 1/Phase 2
Completed	`NCT03899441` - Multimedia Aid Gynecologic Counseling and Consent	N/A
Completed	`NCT02552121` - Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors	Phase 1/Phase 2
Completed	`NCT02001623` - Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors	Phase 1/Phase 2
Completed	`NCT02997553` - Fluorescence for Sentinel Lymph Node Identification in Cancer Surgery	Phase 3
Suspended	`NCT03095664` - Effect of a Lifestyle Intervention on Nutritional Status and Prognosis of Endometrial Cancer Survivors	N/A
Active, not recruiting	`NCT01466777` - Endometrial Cancer and Robotic-assisted Versus Traditional Laparoscopy	N/A
Completed	`NCT01068483` - Safety of BKM120 Monotherapy in Advanced Solid Tumor Patients	Phase 1
Recruiting	`NCT03896113` - Neoadjuvant Celecoxib in Newly Diagnosed Patients With Endometrial Carcinoma	Phase 2
Completed	`NCT05246462` - The Effect of Logotherapy on Mental Health in Gynecological Cancer Patients	N/A
Withdrawn	`NCT04464967` - Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers	Phase 1/Phase 2
Recruiting	`NCT05651282` - Risk Evaluation and Screening to Tailor Prevention and Reduce the Incidence of Endometrial Cancer	Phase 4
Completed	`NCT06187558` - Suspension of the Pelvic and Abdominal Organs During Minimally Invasive Surgery
Completed	`NCT06312917` - Effect of Physical Activity Intervention on Overweight and Obese Patients With Endometrial Cancer	N/A
Active, not recruiting	`NCT03951415` - Durvalumab and Olaparib in Metastatic or Recurrent Endometrial Cancer	Phase 2
Recruiting	`NCT04212910` - Stratifying Endometrial Cancer Patients Using a PET/MRI Prognostic Model
Completed	`NCT02221076` - Probe-based and Needle-based Confocal Laser Endomicroscopy During Gynaecological Procedures.	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

PET/CT in the Management of Patients With Early Stage Endometrial Cancer — ENCA-1

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms